Halozyme Therapeutics Revenue 2006-2021 | HALO

Halozyme Therapeutics annual/quarterly revenue history and growth rate from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Halozyme Therapeutics revenue for the quarter ending June 30, 2021 was $0.136B, a 147.11% increase year-over-year.
  • Halozyme Therapeutics revenue for the twelve months ending June 30, 2021 was $0.412B, a 128.57% increase year-over-year.
  • Halozyme Therapeutics annual revenue for 2020 was $0.268B, a 36.53% increase from 2019.
  • Halozyme Therapeutics annual revenue for 2019 was $0.196B, a 29.06% increase from 2018.
  • Halozyme Therapeutics annual revenue for 2018 was $0.152B, a 52.04% decline from 2017.
Halozyme Therapeutics Annual Revenue
(Millions of US $)
2020 $268
2019 $196
2018 $152
2017 $317
2016 $147
2015 $135
2014 $75
2013 $55
2012 $42
2011 $56
2010 $14
2009 $14
2008 $9
2007 $4
2006 $1
2005 $0
Halozyme Therapeutics Quarterly Revenue
(Millions of US $)
2021-06-30 $136
2021-03-31 $89
2020-12-31 $122
2020-09-30 $65
2020-06-30 $55
2020-03-31 $25
2019-12-31 $54
2019-09-30 $46
2019-06-30 $39
2019-03-31 $57
2018-12-31 $60
2018-09-30 $26
2018-06-30 $35
2018-03-31 $31
2017-12-31 $190
2017-09-30 $64
2017-06-30 $34
2017-03-31 $30
2016-12-31 $39
2016-09-30 $32
2016-06-30 $33
2016-03-31 $42
2015-12-31 $52
2015-09-30 $21
2015-06-30 $43
2015-03-31 $19
2014-12-31 $30
2014-09-30 $15
2014-06-30 $18
2014-03-31 $12
2013-12-31 $12
2013-09-30 $16
2013-06-30 $14
2013-03-31 $12
2012-12-31 $22
2012-09-30 $5
2012-06-30 $8
2012-03-31 $7
2011-12-31 $2
2011-09-30 $23
2011-06-30 $23
2011-03-31 $8
2010-12-31 $4
2010-09-30 $3
2010-06-30 $3
2010-03-31 $3
2009-12-31 $6
2009-09-30 $3
2009-06-30 $1
2009-03-31 $3
2008-12-31 $3
2008-09-30 $2
2008-06-30 $1
2008-03-31 $2
2007-12-31 $1
2007-09-30 $1
2007-06-30 $1
2007-03-31 $1
2006-12-31 $0
2006-09-30 $0
2006-06-30 $0
2006-03-31 $0
2005-12-31 $0
2005-09-30 $0
2005-06-30 $0
2005-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.735B $0.268B
Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29